Shanghai Realbio Technology Co., LTD
Shanghai Realbio Technology Co., LTD founded in 2014, headquartered in Pujiang High-tech Park, Minhang District, Shanghai, is a national high-tech enterprise specializing in accurate detection of tumors. The company has set up regional centers in Hangzhou, Qingdao and other places, with two independent medical laboratories in Shanghai and Qingdao, at the same time in Shanghai and Changsha set up a total of about 3000 square meters in line with GMP standards of production workshop.Based on the core technological advantages of genetic testing, Realbio focuses on the research and development of several early non-invasive tumor detection products, realizing ultra-early, accurate and safe early cancer detection with good compliance, helping early cancer patients seize the'golden window' of clinical intervention, and providing strong support for large-scale tumor detection through comprehensive automation of detection process. Enable the digital upgrade of the IVD industry and become a leader in accurate tumor detection in China in the true sense.
Hangzhou Realbio Gene Technology Co., LTD
Hangzhou Realbio Gene Technology Co., LTD is located in the West Lake Science and Technology Park of Hangzhou City, Zhejiang Province. It is the research and development center of Realbio Group. The company has domestic advanced supporting experimental equipment and powerful biological information analysis platform. The laboratory has complete equipment, including two-level biosafety cabinet, detection equipment Agilent2100, Qubit fluorescence instrument, Nano drop ultramicroscopic spectrophotometer, fluorescence quantitative PCR instrument, electrophoresis instrument, large high-speed centrifuge, gel imaging equipment, etc.In terms of information analysis platform construction, Hangzhou Bioinformation Center is equipped with high-performance computing cluster system, which is committed to providing a full range of solutions and technical support for various clinical studies in the headquarters. The big data analysis platform equipped with the center has achieved 50T flops and over 2PB storage space. Meanwhile, the center has established cooperation with Ali Cloud to build a more powerful computing platform in the cloud, which can support the big data algorithm and system research of PB level genome data.
Hangzhou Realbio occupies an important research and development strategic position, from the collection and research of cutting-edge information in the industry, to the technical perspective of the analysis of potential products, to the formulation of research and development plans and specific implementation plans and the implementation of tests, effectively promote product styling and results transformation.
Qingdao Realbio Precision Medicine Laboratory Co., LTD
Qingdao Realbio Precision Medicine Laboratory Co., LTD as the North China Laboratory service headquarters base carefully built by Realbio Group, was registered in November 2017. Qingdao Realbio is a modern enterprise integrating clinical laboratory services, scientific research and development. Qingdao Realbio service scope radiates the whole North China region, is the Shandong Free Trade Zone Sino-German ecological Park area of the first medical laboratory to obtain clinical gene amplification laboratory technical audit certificate.Relying on the strong technical strength of Realbio, Qingdao Realbio Laboratory mainly provides high-end technical support in the fields of tumor early detection and high-throughput gene detection, and provides excellent and accurate in vitro molecular diagnostic services for our customers. Through the big technology platform, large samples, big database and intelligent analysis software, Realbio Laboratory has made great efforts in the field of life science, medicine and health industry technology. Help the production, study, research and use of blue Marine economic circle to a higher level.
Hunan Branch of Shanghai Realbio Biotechnology Co., LTD
As the Central China production base of Shanghai Realbio Technology Co., LTD., Hunan Branch, established in 2021, is a medical device manufacturer integrating R&D, production and sales. The company has 1200m in line with GMP requirements of class 10,000, class 100,000 clean workshop, at the same time established in line with IS013485 quality management system. The establishment and development of Realbio Hunan branch has accelerated the pace of Realbio to achieve digital, large-scale and intelligent production of medical devices.-
2022
- January
- Chairman of the Board Dr. Qin Nan appeared on CCTV-2 "Dialogue" program
- March
- Realbio is making all-out efforts to help win the battle against COVID-19 in 2022
- April
- Shanghai Realbio Laboratory was approved as a Medical Institution Practice License and the Technical Examination and Acceptance Certificate of Clinical Gene Amplification Laboratory
- May
- COLOWEILL® FDA Approval Medical Device Registration (In Vitro Diagnostic Reagent)
- July
- Realbio passed the test of "Shanghai Science and Technology small Giant (cultivation) Enterprise"
-
2021
- April
- Won the first prize of Shanghai Science and Technology Progress in 2020
- April
- Hunan GMP production workshop landed production
- May
- Qingdao Realbio High Score has passed 3 national indoor quality evaluation
- October
- Shanghai Realbio Medical Laboratory started construction
-
2020
- January
- RIntroduce Zhangjiang Hi-Tech Strategic Investment
- February
- RBT passed the 2020 Shanghai New Coronavirus Nucleic Acid Test Quality Evaluation
- May
- RBT was selected as a list of companies that made outstanding contributions during the epidemic prevention and control period in Minhang District
- June
- RBT became a government-designated third-party new crown nucleic acid testing agency
- August
- RBT passed the 2020 Shandong New Coronavirus Nucleic Acid Test Quality Evaluation
- September
- CEO Nan Qin was elected as the editorial board member of the 5th Editorial Board of Chinese Journal of Microecology
-
2019
- April
- RBT joined the alliance of national digestive early cancer prevention and treatment center
- July
- RBT successfully passed the ISO9001 quality management system certification
- October
- RBT won the Outstanding Enterprise Award of the 8th China Innovation and Entrepreneurship Competition
- November
- RBT won the Best Technology Innovation Award in the Alibaba Maker Competition
- December
- RBT was shortlisted in the "Top 100 Future Medical Care in 2019-China Innovative Devices List"
-
2018
- May
- RBT won the honor of "Minhang Disrict Science and Technology Enterprise" of Shanghai in 2018
- June
- RBT participated in the 7th International Human Microbiome Congress
- July
- RBT successfully organized the 3rd Innovator’s Forum on Human Microbiome
- October
- Undertake 2018(2nd)Summit on Human Microbiome and Health
- December
- Completing A+ round of financing with investment of nearly 100 million yuan led by LUCION CAPITAL
- December
- RBT won the top5 of microorganism companies from "The top 100 healthcare companies of the future in 2018"
-
2017
- June
- RBT successfully organized the 2nd Innovator’s Forum on Human Microbiome
- July
- RBT co-founded the Chinese fecal bacteria library and a fecal bacteria transplantation (FMT) company - Yichang Medical Technology
- September
- RBT completed nearly 10 million US dollars of A Series of financing invested by Marathon Venture Partners
- October
- RBT launched the Chinese Gut Metagenomics Project
- November
- Colobaby™, a child intestinal microbiome screening product, was released
-
2016
- April
- RBT participated in the establishment of the Shandong Medical Laboratory, which won the title of “National Gene Detection Technology Application Demonstration Center”
- May
- RBT established an Agricultural Microbiome Company - Shenzhen Jinrui Biotechnology, Co., Ltd
- June
- RBT successfully organized the 1st Innovator’s Forum on Human Microbiome
- July
- Colohealth®, a gut microbiome detection product, entered the market
- August
- RBT set up a medical laboratory in Guizhou
- September
- RBT raised RMB 40 million ($5.9 million) in a pre-A Series financing round, which was led by Green Pine Capital Partners of Shenzhen
- October
- RBT participated in the 6th International Human Microbiome Congress
- November
- RBT was awarded the honor of "National High-tech Enterprise"
-
2015
- October
- The brand of REALMED was officially launched
- November
- COLOWELL®, the noninvasive early screening services for colorectal cancer, was successfully released
-
2014
- October
-
Realbio Technology (RBT) was established, and the brand of REALGENE was officially launched